These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 692579)

  • 1. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts).
    Dean J; Schechter AN
    N Engl J Med; 1978 Oct; 299(16):863-70. PubMed ID: 692579
    [No Abstract]   [Full Text] [Related]  

  • 2. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts).
    Dean J; Schechter AN
    N Engl J Med; 1978 Oct; 299(15):804-11. PubMed ID: 692564
    [No Abstract]   [Full Text] [Related]  

  • 3. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts).
    Dean J; Schechter AN
    N Engl J Med; 1978 Oct; 299(14):752-63. PubMed ID: 357967
    [No Abstract]   [Full Text] [Related]  

  • 4. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The increasing complexity of sickle cell anemia.
    Warth JA; Rucknagel DL
    Prog Hematol; 1983; 13():25-47. PubMed ID: 6199811
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia.
    Berkowitz LR; Orringer EP
    Blood Cells; 1982; 8(2):283-8. PubMed ID: 7159752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis of antisickling agents.
    Franklin IM; Huehns ER
    Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
    [No Abstract]   [Full Text] [Related]  

  • 9. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.
    Diederich D; Curran M; Odenbaugh A; Diederich A; Core E
    Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the understanding of sickle cell anemia.
    Charache S
    Hosp Pract (Off Ed); 1986 Feb; 21(2):173-8, 182-90. PubMed ID: 2419352
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
    Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
    Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
    Wood KC; Granger DN
    Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival rates and properties of sickle cell anemia red cells treated with nitrogen mustard.
    Roth EF; Wenz B; Lee HB; Fabry M; Chang H; Kaul DK; Baez S; Nagel RL
    Prog Clin Biol Res; 1987; 240():245-61. PubMed ID: 3615491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals.
    Noguchi CT; Rodgers GP; Schechter AN
    Prog Clin Biol Res; 1987; 240():381-91. PubMed ID: 3615501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening newborn infants for sickle hemoglobin.
    Pegelow CH; Pitel P; Judisch J; Randall-David E; Siderits P; Ausbon W
    J Fla Med Assoc; 1988 Oct; 75(10):670-5. PubMed ID: 2461429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.